SMT. HANSA MEHTA LIBRARY
The M. S. University of Baroda

References

References

Adhikary, A., Vavia, P.R., 2008. Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH. Drug Dev. Ind. Pharm. 34, 860–869.

Ali, J., Hasan, S., Ali, M., 2006. Formulation and development of gastroretentive drug delivery system for ofloxacin. Methods Find Exp Clin Pharmacol 28(7), 433-439.

Amidon G.E., Secreast, P.J., Mudie D., 2009. Particle, powder and compact characterization. In: Qiu, Y., Chen, Y., Zhang, G. (eds), Developing solid oral dosage forms-Pharmaceutical theory and practice, 1st edn, Academic Press, Ma, USA, pp 168-171

Antos, D., Schneider-Brachert, W., Bastlein, E., Hanel, C., Haferland, C., Buchner, M., Meier, E., Trump, F., Stolte, M., Lehn, N., Bayerdörffer, E., 2006. 7-day triple therapy of helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 11, 39–45.

Asmussen, B., Cremer, K., Hoffmann, H.R., Ludwig, K., Roreger, M., 2001. Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract. US Patent 6,290,989, Sep.18

Atherton JC, Cullen DJE, Kirk GE, Hawkey CJ, Spiller RC. Enhanced eradication of Helicobacter pylori by pre- versus postprandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Aliment Pharmacol Ther 1996; 10: 631-635.

Augsburger, L.L, 2008. Hard and soft shell capsules. In: Banker, G.S., Rhodes, C.T., (eds), Modern Pharmaceutics. 4th edn, Informa Healthcare, pp 335-380.

Bardonnet, P.L., Faivre, V., Pugh, W.J., Piffaretti, J.C., Falson, F., 2006. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Controlled Release 111,1-18.

Bechgard, H., Nielsen, G.H., 1978. Controlled-release multiple-units and single-unit doses. A literature review. Drug Dev. Ind. Pharm. 4, 53–67.

Borgquist, P., Korner, A., Piculell, L., Larsson, A., Axelsson, A., 2006. A model for the drug release from a polymer matrix tablet - effects of swelling and dissolution. J. Controlled Release 113, 216-225.

Bytzer, P., O'Morain, C., 2005. Treatment of Helicobacter pylori. Helicobacter 10 (suppl. 1) , 40–46.

Chakraborty , P., 2001. A Textbook of microbiology. First edn. New Central Book Agency, Kolkata. pp 369.

Chauhan, B., Shimpi, S., Mahadik, K.R., Paradkar, A., 2004. Preparation and evaluation of floating risedronate sodium Gelucire® 39/01 matrices. Acta Pharm. 54, 205–214.

Chavanpatil, M., Jain, P., Chaudhari, S., Shear, R., Vavia, P., 2005. Development of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation. Int. J. Pharm. 304,178–184.

Chavanpatil, M.D., Jain, P., Chaudhari, S., Shear, R., Vavia, P.R., 2006. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 316, 86-92.

Chen, J., Blevins, W.E., Park, H., Park, K., 2000. Gastric retention properties of superporous hydrogel composites. J. Controlled Release 64, 39–51

Conway, B.R., 2005. Drug delivery strategies for the treatment of helicobacter pylori Infections. Curr Pharm Design 11, 775-790.
Cooreman, M. P., Krausgrill, P., Hengels, K. J., 1993. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrobial Agents and Chemotherapy. 37(7), 1506–1509.

Costa, P., Lobo, J.M.S., 2001. Review: Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13, 123–133.

Curatolo, W.J., Lo, J., 1995. Gastric retention system for controlled drug release. US Patent 5,443,843, Aug 22.

Dave, B. S., Amin, A. F., Patel, M. M.,2004. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech 5 (2) Article 34, 1-6.

Davis, S.S., 2005. Formulation strategies for absorption windows. Drug Discovery Today. 2005, 10(4), 249-257.

Derringer, G., Suich, R., 1980. Simultaneous optimization of several responses variables. Journal of Quality Technology, 12 (4), 214–219.

Deshpande, A.A., Rhodes, C.T., Shah, N.H., Malick, A.W., 1996. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 22: 531–539.

Deshpande, A. A., Shah, N.H., Rhodes, C.T., Malick, W., 1997. Development of a novel controlled release system for gastric retention. Pharm Res 14(6), 815-819.

Dodou, D., Breedveld, P., Wieringa, P.A., 2005. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur. J. Pharm. Biopharm. 60, 1–16.

Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-741.

Durig, T., Fassihi, R., 2000. Evaluation of floating and sticking extended release delivery systems: an unconventional dissolution test. J. Controlled Release 67, 37-44.

Dzierzanowska-Fangrat, K., Lehours, P., Megraud, F., Dzierzanowska, D., 2006. Diagnosis of Helicobacter pylori infection. Helicobacter 11 (s1), 6–13.

Efentakis, M., Koutlis, A., Vlachou, M., 2000. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech 1(4), Article 34, 1-9.

El-Gibaly, I., 2002. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int. J. Pharm. 249, 7-21.

El-Kamel, A.H., Sokar, M.S., Al Gamal, S.S., Naggar, V.F., 2001. Preparation and evaluation of ketoprofen floating oral delivery system. Int. J. Pharm. 220, 13–21.

Emami, M.H., Saberfiroozi M.M, Arj, A., Taghavi, A.R., Lankarani, K.B., Dehbashi, N., Fattahi, M.R., Alizadeh, M., Kaviani, J.K., . Bahri-Najafi, R., Geramizadeh, B., Esmaeili, A., 2006. Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. World J Gastroenterol 12(39), 6310-6315.

Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.

Fischbach, W., On-On Chan, A., Chun-Yu Wong, B., 2005. Helicobacter pylori and gastric malignancy. Helicobacter 10 (suppl. 1) , 34–39.

Flashner, B.M., Rosenberger, V., Dahan, M., Lerner, Y., 2002. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates. US Patent 6,476,006, Nov.5

Follonier, N., Doelker, E., 1992. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. S. T. P. Pharma Sci. 2, 141–158.

Fu X.C. , Wang G.P., Liang W.Q. , Chow M.S.S., 2004. Prediction of drug release from HPMC matrices: effect of physicochemical properties of drug and polymer concentration. J. Controlled Release 95, 209–216.

Garg, S., Sharma, S., 2003. Gastroretentive Drug Deliver y Systems. Pharmatech Business Briefing, 160-166.

Gibaldi, M., Feldman, S., 1967. Establishment of sink conditions in dissolution rate determinations – theoretical considerations and application to non-disintegrating dosage forms, J. Pharm. Sci. 56, 1238–1242.

Gisbert, J.P., Gisbert, J.L., Marcos, S., Moreno-Otero., R., Pajares, J.M., 2007. Levofloxacin vs ranitidine bismuth citrate containing therapy after H.Pylori treatment failure. Helicobacter 12(1), 68-73.

Gomez-Burgaz M., García-Ochoa, B. and Torrado-Santiag, S., 2008. Chitosan–carboxymethylcellulose interpolymer complexes for gastric-specific delivery of clarithromycin. Int J Pharm 359, 135-148.

Goole J., Amighi, K., Vanderbist, F., 2008. Evaluation and floating enhancement of levodopa sustained release floating minitablets coated with insoluble acrylic polymer. Drug Dev. Ind. Pharm. 34, 827–833.

Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterol 2000; 118: S2-S8.

Hadjicostas, E., 2003. Validation of analytical methods. In: Wenclawaik, B., Koch, M., Hadjicostas, E. (eds), Quality assurance in analytical chemistry -Training and teaching, Springer Verlag, Berlin.

Hladik, W., Norenberg, J, 2000. Fundamentals of medical radionuclides. In: Gennaro, A.R., (ed), Remington: The science and practice of pharmacy, Lippincot Williams and Wilkins, Vol. 2, pp478-480

Hamdani, J., Goole, J., Moes, A.J., Amighi, K., 2006. In vitro and in vivo evaluation of floating riboflavin pellets developed using the melt pelletization process. Int. J. Pharm. 322, 104-112.

Hamdani, J., Moes, A.J., Amighi, K., 2006. Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization. Int. J. Pharm. 322, 96-103.

Hassan, I. J., Stark, R.M., Greenman, J., Millar, M.R.,1999. Activities of β-Lactams and Macrolides against Helicobacter pylori. Antimicrobial Agents and Chemotherapy. 43(6), 1387–1392.

Hejazi, R., Amiji, M., 2003. Chitosan based gastrointestinal delivery systems. J. Controlled Release 89, 151-165.

Higo S, Ori K, Takeuchi H, Yamamoto H, Hino T, Kawashima Y.A novel evaluation method of gastric mucoadhesive property in vitro and the mucoadhesive mechanism of tetracycline-sucralfate acidic complex for eradication of Helicobacter pylori. Pharm Res 2004; 21: 413-419.

Higuchi, T., 1963. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci. 52, 1145–1149.

Hirschl A.M., Rotter M.L. Amoxicillin for the treatment of Helicobacter pylori infection. J Gastroenterol 1996; 31 S9: 44-47.

Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol 2002; 54: 341-347.

Huang J-Q, Hunt RH. Review: eradication of Helicobacter pylori. Problems and recommendations. J Gastroenterol Hepatol 1997; 12: 590-598.

Inagi, T., Shirai, H., Yamaguchi, N., Nishino, T., 2003. Medicinal compositions adhering to stomach/duodenum. US Patent 6,582,720, June 24.

Indian Pharmacopoeia, 2007. Indian Pharmacopoeia Commission, Ghaziabad, India.

ISP technical bulletin, 2007.

Jain, S.K., Agrawal, G.P., Jain, N.K., 2006. Evaluation of porous carrier based floating orlistat microspheres for gastric delivery. AAPS PharmSciTech 7(4), Article 90, E1-E9.

Jain, S.K, Awasthi, A.M., Jain,N.K., Agrawal, G.P., 2005. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J. Controlled Release 107, 300– 309.

Jimenez-Castellanos M. R., Zia, H., Rhodes, C.T., 1994. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int. J. Pharm.105, 65-70.

Jiménez-Martínez, I., Quirino-Barredaand, T., Villafuerte-Robles, L.,2008. Sustained delivery of captopril from floating matrix tablets. Int .J.Pharm. 362, 37-43.

Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits. J. Controlled Release 79, 71-79.

Kagan, L., Lapidot, N., Afargan, M., Kirmayer, D., Moor, E., Mardor, Y., Friedman, M., Hoffman, A., 2006. Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans. J. Controlled Release 113, 208-215.

Khan, G.M.,2001. Controlled release oral dosage forms: some recent advances in matrix type drug delivery systems. The Sci. 1(5), 350-354.

Kiil, S., Dam-Johansen, K., 2003. Controlled drug delivery from swellable hydroxypropylmethylcellulose matrices: model-based analysis of observed radial front movements. J. Controlled Release 90, 1–21.

Klausner, E.A., Eyal, S., Lavy, E., Friedman, M., Hoffman, A., 2003. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J. Controlled Release 88, 117-126.

Klausner, E.A., Lavy, E., Friedman, M., Hoffman, A., 2003. Expandable gastroretentive dosage forms. J. Controlled Release 90,143–162

Korsmeyer, R.W., Gurny, R., Doelker, E.M., Buri, P., Peppas, N.A., 1983. Mecanism of solute release from porous hydrophilic polymers, Int. J.Pharm. 15, 25–35.

Kuchekar B.S., Singavi, A.A., Late, S.G., Shinde, B.S., 2003. Indian Drugs 40(1), 44-45.

Kulpers EJ, Janssen MJR, de Boer WA. Good bugs and bad bugs: indications and therapies for Helicobacter pylori eradication. Curr Opin Pharmacol 2003; 3: 480-485.

Lee, J.H., Park, T.G., Choi, H.K. 1999. Development of oral drug delivery system using floating microspheres. J. Microencapsulation 16(6), 715 –729.

Lewis, G.A., Mathieu, D., Phan-Tan-Luu,. R., 1999. Pharmaceutical Experimental Design. Marcel Dekker Inc., New York.

Li, S., Lin., S., Chien, Y.W., Daggy, B. P., Mirchandani, H.L., 2001. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2 (1) article 1

Li, S., Lin,S., Daggy,B.P., Mirchandani, H.L., Chien, Y.W., 2002. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev. Ind. Pharm. 28(7), 783–793.

Li, S., Lin, S., Daggy, B.P., Mirchandani H.L., Chien, Y. W., 2003. Effect of HPMC and carbopol on the release and floating properties of gastric floating drug delivery system using factorial design, Int J Pharm. 253, 13–22.

Liu, Q., Fassihi, R. 2008. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm 348, 27–34.

Liu, Z., Lu, W., Qian, L., Zhang, X., Zeng, P., Pan, J., 2005. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J. Controlled Release 102, 135–144.

Lozniewski A, de Korwin J.D., Muhale F., Jehl F., 1998. Gastric diffusion of antibiotics used against Helicobacter pylori. Int J Antimicrob Agent 9, 181-193.

Lozniewski A., Duprez A., Renault C., Muhale F., Conroy M.C., Weber M., 1999. Gastric penetration of amoxicillin an a human Helicobacter pylori- infected model. Antimicrob Agents Chemother 43, 1909-1913.

Maa, N., Xua, L., Wanga, Q., Zhanga, X., Zhanga, W., Lia, Y., Jina, L., Li, S., 2008. Development and evaluation of new sustained-release floating microspheres. Int J Pharm 358, 82-90.

Majithiya, R., Murthy, R.S.R., 2005. Chitosan-based mucoadhesive microspheres of clarithromycin as a delivery system for antibiotic to stomach. Curr Drug Del 2(3), 235-242.

Maria, D., Queiroz, M., Luzza, F., 2006. Epidemiology of Helicobacter pylori infection. Helicobacter 11 (S1), 1–5

Marshall, B., 2002. Helicobacter pylori: 20 years on. Clin. Med. 2, 147– 152.

Marshall B.J., Warren J.R., 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315.

Marshall, K., 1987. Compression and consolidation of powdered solids. In: Lachman, L., Lieberman, H.A., Kanig, J.L. (eds.), The Theory and Practice of Industrial Pharmacy, Varghese Publishing House, Mumbai, pp. 66-68.

Marzio, L., Coraggio, D., Capodicasa, S., Grossi, L., Cappello, G., 2006. Role of the preliminary susceptibility testing for initial and after failed therapy of helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 11 (4), 237–242.

Mashru, R. C., Sutariya V. B., Sankalia M.G., Parikh, P. P., 2005. Development and evaluation of fast dissolving film of Salbutamol sulphate. Drug Dev. Ind. Pharm. 1, 25–34.

McDowell, A., Nicoll, J.J., McLeod, B.J., Tucker, I.G., Davies, N.M., 2005. Gastrointestinal transit in the common brushtail possum measured by gamma scintigraphy. Int. J. Pharm. 302, 125–132.

Megraud F., 2000. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicob. Agents 16, 507-509.

Megraud F., 2001. Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist Updat 4. 18-186.

Megraud, F., Trimoulet, P., Lamouliatte, H., Boyanova, L., 1991. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrobial Agents and Chemotherapy 35(5), 869–872.

Michailova, V., Titeva, S.T., Kotsilkova, R., Krusteva, E., Minkov, E., 2001. Influence of hydrogel structure on the processes of water penetration and drug release from mixed hydroxypropylmethylcellulose/thermally pregelatinized maxy maize starch hydrophilic matrices. Int. J. Pharm. 222, 7–17.

Miranda, A., Millan, M., Caraballo, I., 2006. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. Int. J. Pharm. 311, 75-81.

Mitchell, K., Ford, J.L., Armstrong, D.J., Elliott, P.N.C., Rostron, C., Hogan, J.E., 1993. The influence of concentration on the release of drugs from gels and matrices containing Methocel. Int. J. Pharm.100, 155-163.

Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastrooesophageal reflux disease. Gastroenterol 2001; 121: 1120-1126.

Moes, A .J., 1993. Gastroretentive dosage forms, Crit. Rev. Ther. Drug Carrier Syst. 10 (2), 143–195.

Murata, Y., Kofuji, K., Kawashima, S., 2003. Preparation of floating alginate gel beads for drug delivery to the gastric mucosa. J. Biomater. Sci. Polymer Edn. 14(6), 581–588.

Murray C.J.L., Lopez A.D., 1997. Alternative projections of mortality and disability by cause 1990-2020-global burden of disease study. Lancet 349, 1498-1504.

Narendra, C., Srinath, M. S., Babu, Ganesh, 2006. Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention. AAPS PharmSciTech 7 (2), article 34E1-E7

Nur, A.O., Zhang, J.S., 2000. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev. Ind. Pharm. 26(9), 965–969.

Ofori-Kwakye, K., Fell, J.T., Sharma, H.L., Smith, A.M., 2004. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. Int. J. Pharm. 270, 307–313.

Omidian, H., Rocca, J.G., Park, K., 2005. Advances in superporous hydrogels. J. Controlled Release 102, 3–12.

O'Neil, M.J., 2006. The Merck index, Merck and Company Inc., NJ, USA. 14th edition

Ozdemir, N., Ordu, S., Ozkan, Y., 2000. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev. Ind. Pharm. 26(8), 857–866.

Patel, V.F., Patel, N.M., 2006. Intragastric floating drug delivery system of cefuroxime axetil: in vitro evaluation. AAPS PharmSciTech 7 (1), Article 17, E1-E7.

Paterakis, P. G., Korakianiti, E. S., Dallas, P. P., Rekkas, D. M., 2002. Evaluation and simultaneous optimization of some pellets characteristics using 3^3 factorial design and the desirability function. Int J Pharm, 248, 51–60.

Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug release from polymers, Pharm. Acta Helv. 60, 110–111.

Perri, F., Qasim, A., Marras, L., O'Morain, C., 2003. Treatment of Helicobacter pylori infection. Helicobacter 8 (Suppl.1), 53–60.

Petersen W.L., 1991. Helicobacter pylori and peptic ulcer disease. N Eng J Med 324: 1043-1048.

Prado, E., Loy-Gerala, C., 2006. Comparative Helicobacter pylori eradication treatment: triple-drug (amoxicilin, clarithromycin and rabeprazole) Vs. levofloxacin plus rabeprazole. Gastrointestinal Endoscopy 63(5), AB161,M1285.

Rajinikanth, P.S. Balasubramaniam, J. and Mishra, B. 2007. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of *Helicobacter pylor.* Int J Pharm 335, 114-122.

Risbud, M.V., Hardikar, A.A., Bhat, S.V., Bhonde, R.R., 2000. pH-sensitive freeze-dried chitosan–polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery. J. Controlled Release 68, 23-30.

Ritger, P.L., Peppas, N.A., 1987. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 5, 37–42.

Rocca ,J.G., Omidian, H., Shah, K., 2003. Progresses in Gastroretentive Drug Delivery Systems. Pharmatech Business Briefing, 152-156.

Rouge, N., Allemann, E., Gex-Fabry, M., Balant, L.,, Cole, E.T., Buri, P., Doelker, E.,1998. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharmaceutica Acta Helvetiae 73, 81–87.

Rowe, R.C, Sheskey, P.J., Owen, S.C., 2006. Handbook of Pharmaceutical Excipients, Fifth edition, Pharmaceutical Press, London.

Sawicki, W., 2002. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur. J. Pharm. Biopharm. 53, 29–35.

Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for *Helicobacter pylori* infection. J Pharm Pharmacol. 1999;51:667-672.

Sharara, A.I., Chaar, H.F., Aoun, E., Abdul-Baki, H., Araj, G.F., Kanj, S.S., 2006. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 11(4), 231–236.

Sharma, S., Pawar, A., 2006. Low density multiparticulate system for pulsatile release of meloxicam.Int. J. Pharm. 313, 150-158.

Siepe, S., Lueckel, B., Kramer, A., Ries, A., Gurny, R., 2008. Assessment of tailor-made HPMC-based matrix minitablets comprising a weakly basic drug compound. Drug Dev. Ind. Pharm. 34, 46–52.

Siepmann, J., Peppas, N.A., 2001. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Del. Rev. 48, 139–157.

Simala-Granta, J.L., Zopf, D., Taylor, D.E., 2001. Antibiotic susceptibility of attached and free-floating Helicobacter pylori. J. Antimicrobial Chemother. 47, 555-563

Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Controlled Release 63, 235-259.

Soppimath, K.S., Aminabhavi, T.M., Agnihotri, S.A., Mallikarjuna, N.N., Kulkarni P. V., 2006. Effect of coexcipients on drug release and floating property of nifedipine hollow microspheres: A novel gastro retentive drug delivery system. J. Applied Polymer Sci. 100, 486–494.

Sriamornsak, P., Thirawong, N., Puttipipatkhachorn, S., 2004. Morphology and buoyancy of oil-entrapped calcium pectinate gel beads. The AAPS Journal 6 (3) Article 24, 1-7

Srivastava, A. K., Wadhwa, S., Ridhurkar, D., Mishra, B., 2005. Oral sustained delivery of atenolol from floating matrix tablets - formulation and in vitro evaluation. Drug Dev. Ind. Pharm. 31, 367–374.

Streubel, A., Siepmann, J. Bodmeier, R. 2006a. Drug delivery to the upper small intestine window using gastroretentive technologies. Current Opinion in Pharmacology 6, 501-508.

Streubel, A., Siepmann, J., Bodmeier, R., 2006b. Gastroretentive drug delivery systems. Expert Opin. Drug Deliv. 3(2), 217-233.

Suerbaum, S., Michetti, P., 2002. Helicobacter Pylori infection. N Engl J Med 347(15), 1175-1186.

Sungthongjeen, S., Sriamornsak, P. Puttipipatkhachorn, S., 2008. Design and evaluation of floating multi-layer coated tablets based on gas formation. Eur. J. Pharm. Biopharm. 69 (1), 255-263.

Sweetman, S.C, 2005. Martindale – The Complete Drug Reference, Pharma Press, 34th edn., pp 155-156.

Talukdar, R., Fassihi, R., 2004. Gastroretentive delivery systems: A mini review. Drug Dev. Ind. Pharm. 30(10), 1019–1028.

Talwar, N., Sen, H., Staniforth, J.N., 2005. Orally administered controlled drug delivery system providing temporal and spatial control. US Patent 6,960,356, July 17

Tang, Y.D., Venkatraman, S.S., Boey, F.Y.C. and Wang, L. 2008. Sustained release of hydrophobic and hydrophilic drugs from a floating dosage form. Int J Pharm 336, 159-165.

Tortora G.J., 2003. Principles of Anatomy and Physiology. Tenth edn. John Wiley and Sons.pp 851.

Tritt-Goc, J., Pislewski, N., 2002. Magnetic resonance imaging study of the swelling kinetics of hydroxypropylmethylcellulose (HPMC) in water. J. Controlled Release 80, 79-86.

Umamaheshwari, R. B., Jain, S., Jain, N. K., 2003a. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Del 10, 151–160.

Umamaheshwari, R. B., Jain, S., Bhadra, D., Jain, N. K., 2003b. Floating microspheres bearing acetohydroxamic acid for the treatment of *Helicobacter pylori.* J Pharm. Pharmacol. 55, 1607–1613.

Umamaheshwari, R.B., Jain, N.K., 2004. Receptor mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J. Controlled Release 99, 27–40.

Umamaheshwari, R.B., Ramteke, S., Jain, N.K., 2004, Anti–helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model, AAPS PharmSciTech 5 (2) Article 32, 1-9

United States Pharmacopeia-30 / National Formulary - 25, 2007. US Pharmacopeial convention, Rockville, MD.

Velasco, M.V., Ford, J.L., Rowe, P., Rajabi-Siahboomi, A.R., 1999. Influence of drug:hydroxypropylmethylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC tablets. J. Control. Rel. 57, 75–85.

Wagner, J.G., 1969. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules, J. Pharm. Sci. 58, 1253–1257.

Walsh, J.H., Peterson, W.L., 1995. The treatment of *helicobacter pylori* infection in the management of peptic ulcer disease. N Engl J Med 333(15), 984-991.

Warren, J.R., 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1, 1273–1275.

Watanabe, Y., Aoyama, N., Shirasaka, D., Maekawa, S., Kuroda, K., Miki, I., 2003. Levofloxacin based triple therapy as a second-line treatment after failure of *Helicobacter pylori* eradication with standard triple therapy. Dig Liver Dis 35, 711–715.

Wei, Z., Yu, Z., Bi, D., 2001. Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug. Drug Dev. Ind. Pharm. 27(5), 469–474.

Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A.M., 1998. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Controlled Release 55, 3-12.

WHO The World Health Report 1996 - Fighting disease, fostering development, 1996 published by World Health Organization, Geneva.

Wong, P. S. L., Dong, L.C., Edgren, D.E., Theeuwes, F., Gardner, P.I., Jao, F., Wan, J. J., 2000. Prolonged release active agent dosage form adapted for gastric retention. US Patent 6,120,803, Sep.19.

www.rxlist.com

Yang, L., Eshraghi, J., Fassihi, R. 1999. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J. Control. Rel. 57, 215–222

Yang, I., Fassihi, R., 1996. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J Pharm Sci 85(2),170-173.

Yang, L., Fassihi, R., 1997. Examination of solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple layer asymmetric configuration delivery system. Int. J. Pharm. 155, 219-229.

Yang, Z., Song, B., Li, Q., F. H., Ouyang, F., 2004. Preparation of microspheres with microballoons inside for floating drug-delivery systems. J. Applied Polymer Sci. 94, 197–202.

Yokel R.A., Dickey KM, Goldberg AH. Selective adherence of a sucralfate-tetracycline complex to gastric-ulcers - implications for the treatment of Helicobacter-pylori. Biopharm Drug Dispos 1995; 16: 475-479.

Zhou, H., 2003. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J. Clin. Pharmacol. 43, 211-227.